MREO

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.01
Percentage change 0.27	%

Peers: SRPT FATE KURA ADVM RIGL XERS IMUX PRQR CLSD MTEM

| Held by: HRTS CANC GWX APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	11.19%	Shs Outstand	154.73M	Perf Week	-0.80%
Market Cap	578.69M	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-3.87%	Shs Float	137.43M	Perf Month	-7.65%
Income	-	PEG	-	EPS next Q	0.01	Inst Own	59.44%	Short Float	4.83%	Perf Quarter	-16.89%
Sales	-	P/S	-	EPS this Y	-4.17%	Inst Trans	7.05%	Short Ratio	8.75	Perf Half Y	-12.00%
Book/sh	0.47	P/B	7.98	EPS next Y	16.00%	ROA	-	Short Interest	6.63M	Perf Year	79.81%
Cash/sh	0.52	P/C	7.19	EPS next 5Y	-	ROE	-	52W Range	1.97 - 5.02	Perf YTD	61.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	41.78%	ROI	-	52W High	-25.50%	Beta	0.91
Dividend TTM	-	Quick Ratio	6.10	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	89.85%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	-21.83%	Oper. Margin	-	RSI (14)	48.44	Volatility	5.32% 6.32%
Employees	33	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	7.17
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.82	Prev Close	3.73
Sales Surprise	-	EPS Surprise	-11.11%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	758.08K	Price	3.74
SMA20	3.55%	SMA50	-6.53%	SMA200	-0.02%	Trades		Volume	619,994	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Jefferies	Buy	$7
Jun-13-24	Initiated	Robert W. Baird	Outperform	$8
Oct-13-23	Resumed	BTIG Research	Buy	$4
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight	$4
May-05-21	Initiated	BTIG Research	Buy	$10
Apr-05-21	Initiated	Needham	Buy	$10

Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
08:21AM	Loading…
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:30AM	Loading…
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
07:46AM	Loading…
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.52%
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. (GlobeNewswire) +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout (Zacks)
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors (Barrons.com) +62.50% +30.00%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges (Yahoo Finance Video)
10:21AM	Why Mereo BioPharma Shares Are Jumping Today (Benzinga)
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report (MarketWatch)
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan (GlobeNewswire) -5.12%
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +8.77%
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire)
May-17-22 08:00AM	Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors (GlobeNewswire)
May-09-22 07:45AM	Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease (Benzinga) -31.30%
07:00AM	Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema (GlobeNewswire)
May-06-22 05:12PM	Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
05:12PM	Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
Apr-22-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-06-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-22 04:01PM	Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire) +7.69%
Mar-03-22 08:30AM	Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022 (GlobeNewswire)
Mar-01-22 08:00AM	Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors (GlobeNewswire)
Feb-10-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -6.67%
Jan-12-22 01:59PM	Do Hedge Funds Love Mereo BioPharma Group plc (MREO)? (Insider Monkey)
Dec-29-21 01:19AM	UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial (American City Business Journals)
Dec-22-21 07:00AM	UAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease (GlobeNewswire)
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com) +7.55%
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Dec-13-21 07:00AM	Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereos Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting (GlobeNewswire)
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Nov-30-21 07:00AM	Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors (GlobeNewswire)
Nov-09-21 08:00AM	Mereo BioPharma to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-21 09:00AM	Data from Investigator-sponsored Trial of Mereo BioPharmas alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-21 10:30AM	2 Growth Stocks That Could Deliver 1,000% Returns (Motley Fool)
Oct-26-21 10:26AM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) (Insider Monkey)
08:00AM	Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency (GlobeNewswire)
Oct-13-21 08:00AM	Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment (GlobeNewswire)
Oct-01-21 04:31PM	Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting (GlobeNewswire) +7.02% -10.04%
Sep-20-21 08:00AM	Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors (GlobeNewswire) -5.30%
Sep-09-21 08:00AM	Mereo BioPharma to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-02-21 08:00AM	Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-19-21 07:04PM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) (Insider Monkey)

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scots-Knight Denise	Chief Executive Officer	Sep 13 '24	Sale	4.22	60,046	253,454	808,921	Sep 16 08:50 PM
Scots-Knight Denise	Chief Executive Officer	Sep 12 '24	Sale	4.47	28,611	127,968	868,967	Sep 16 08:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 13 '24	Sale	4.22	10,937	46,165	78,630	Sep 16 08:49 PM
Lewicki John A.	Chief Scientific Officer	Sep 12 '24	Sale	4.47	5,212	23,312	89,567	Sep 16 08:49 PM
Sermon Charles	General Counsel	Sep 13 '24	Sale	4.22	20,946	88,413	219,061	Sep 16 08:48 PM
Sermon Charles	General Counsel	Sep 12 '24	Sale	4.47	9,980	44,638	240,007	Sep 16 08:48 PM
Fox Christine Ann	Chief Financial Officer	Sep 13 '24	Sale	4.22	19,158	80,866	89,285	Sep 16 08:47 PM
Fox Christine Ann	Chief Financial Officer	Sep 12 '24	Sale	4.47	9,128	40,827	108,443	Sep 16 08:47 PM
Hughes-Wilson Alexandra	See Remarks	Sep 13 '24	Sale	4.22	100,312	423,417	50,475	Sep 16 08:46 PM
Hughes-Wilson Alexandra	See Remarks	Sep 12 '24	Sale	4.47	47,798	213,786	150,787	Sep 16 08:46 PM
Sermon Charles	General Counsel	Sep 11 '24	Option Exercise	0.00	65,600	0	249,987	Sep 13 04:57 PM
Fox Christine Ann	Chief Financial Officer	Sep 11 '24	Option Exercise	0.00	60,000	0	117,571	Sep 13 04:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 11 '24	Option Exercise	0.00	46,000	0	94,779	Sep 13 04:49 PM
Scots-Knight Denise	Chief Executive Officer	Sep 11 '24	Option Exercise	0.00	188,060	0	897,578	Sep 13 04:49 PM
Hughes-Wilson Alexandra	See Remarks	Sep 11 '24	Option Exercise	0.99	208,333	206,416	242,881	Sep 13 04:47 PM
Alexandra Hughes-Wilson	Officer	Sep 12 '24	Proposed Sale	4.66	148,110	690,193		Sep 12 04:05 PM
Scots-Knight Denise	Officer	Sep 12 '24	Proposed Sale	4.66	88,657	413,142		Sep 12 04:05 PM
Sermon Charles	Officer	Sep 12 '24	Proposed Sale	4.66	30,926	144,115		Sep 12 04:05 PM
Lewicki John A.	Officer	Sep 12 '24	Proposed Sale	4.66	16,149	75,254		Sep 12 04:05 PM
Fox Christine Ann	Officer	Sep 12 '24	Proposed Sale	4.66	28,286	131,813		Sep 12 04:05 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Option Exercise	1.44	105,244	151,116	105,244	Aug 23 06:13 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Sale	4.43	105,244	466,210	0	Aug 23 06:13 PM
Deepika Pakianathan	Director	Aug 22 '24	Proposed Sale	4.43	105,244	466,210		Aug 22 06:35 PM
Sermon Charles	General Counsel	Jun 26 '24	Sale	3.39	32,187	109,217	184,387	Jun 27 04:15 PM
Sermon Charles	General Counsel	Jun 25 '24	Sale	3.69	14,202	52,461	216,574	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 26 '24	Sale	3.39	16,808	57,033	48,779	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 25 '24	Sale	3.69	7,416	27,394	65,587	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 26 '24	Sale	3.39	29,439	99,892	57,571	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 25 '24	Sale	3.69	12,990	47,984	87,010	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 26 '24	Sale	3.39	92,273	313,101	709,518	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 25 '24	Sale	3.69	40,712	150,386	801,791	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 26 '24	Sale	3.39	22,968	77,935	34,548	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 25 '24	Sale	3.69	10,134	37,434	57,516	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 21 '24	Option Exercise	0.00	69,000	0	73,003	Jun 25 06:21 PM
Scots-Knight Denise	Chief Executive Officer	Jun 21 '24	Option Exercise	0.00	282,090	0	842,503	Jun 25 06:15 PM
Sermon Charles	General Counsel	Jun 21 '24	Option Exercise	0.00	98,400	0	230,776	Jun 25 06:14 PM
Fox Christine Ann	Chief Financial Officer	Jun 21 '24	Option Exercise	0.00	90,000	0	100,000	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	Jun 21 '24	Option Exercise	0.00	60,000	0	67,650	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Option Exercise	1.23	168,333	206,416	100,983	May 23 09:54 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Sale	2.97	100,432	297,788	32,568	May 23 09:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Mereo Biopharma Group Plc ADR

Upgrade your FINVIZ experience